RxDoctor Payments Data

Bharat Vakharia, MD

Internal Medicine · Hartselle, ALNPI 1992896336

Payments from drug & device makers

$715in general payments, 2019–2025

Across 46 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$197
  • Novo Nordisk$123
  • Johnson & Johnson$121
  • Sanofi-aventis U.S. LLC$61
  • Boston Scientific$42
  • AstraZeneca$41
  • plus $131 from 7 others

What the payments were for

  • Food & beverage$715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$715 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$126,878
Medicare patients
286
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$194,284
JanuviaSitagliptin Phosphate191$132,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$76,391
OzempicSemaglutide51$64,203
JanumetSitagliptin Phos/Metformin Hcl41$53,150
JardianceEmpagliflozin102$44,472
TrulicityDulaglutide73$44,043
LinzessLinaclotide65$37,431
XareltoRivaroxaban107$37,375
TivicayDolutegravir Sodium21$34,327
MyrbetriqMirabegron70$30,405
EntrestoSacubitril/Valsartan61$27,146
FarxigaDapagliflozin Propanediol59$23,464
Tresiba Flextouch U-100Insulin Degludec28$22,414
TradjentaLinagliptin26$18,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$194,284381 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix, Anoro Ellipta$197$106,555186 claims
Novo NordiskOzempic$123$64,20351 claims
Lilly USA, LLCTrulicity$11$44,04373 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$41$39,649106 claims
AbbVieLinzess$15$37,43165 claims
Johnson & JohnsonXarelto$121$37,375107 claims
Astellas Pharma US IncMyrbetriq$26$30,40570 claims
Sanofi-aventis U.S. LLCMultaq$61$8,48113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Hartselle

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →